drugset / Trial / NCT02608710

RDEA3170 PK/PD Study

NCT02608710

Phase 1 Completed 40 enrolled Ardea Biosciences, Inc.
RandomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to examine the pharmacokinetic and pharmacodynamic effect of RDEA3170 when given as single or multiple doses

Timeline

Start
2015-11
Primary completion
2015-12
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Verinurad Small molecule 4.5 mg
Subject Verinurad Small molecule 6 mg
Subject Verinurad Small molecule 12 mg

Indications